Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

ID Pavord, S Korn, P Howarth, ER Bleecker, R Buhl… - The Lancet, 2012 - thelancet.com
Background Some patients with severe asthma have recurrent asthma exacerbations
associated with eosinophilic airway inflammation. Early studies suggest that inhibition of …
Save Cite Cited by 2426 Related articles All 14 versions

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a …

JM FitzGerald, ER Bleecker, P Nair, S Korn, K Ohta… - The Lancet, 2016 - thelancet.com
Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …
Save Cite Cited by 1336 Related articles All 7 versions
[HTML] nih.gov

[HTML][HTML] Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: position paper of Ärzteverband Deutscher …

…, C Taube, E Jensen-Jarolim, S Korn… - Allergologie …, 2020 - ncbi.nlm.nih.gov
Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with
allergic and atopy-associated diseases has faced major challenges. Recommendations for “…
Save Cite Cited by 47 Related articles All 13 versions

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo …

…, K Murphy, JF Maspero, C O'Brien, S Korn - The Lancet …, 2015 - thelancet.com
Background Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations.
Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts …
Save Cite Cited by 1221 Related articles All 9 versions
[HTML] nih.gov

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …

…, O Kobrynska, P Koleckar, S Korn… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …
Save Cite Cited by 204 Related articles All 14 versions
[HTML] nejm.org

[HTML][HTML] Mepolizumab for eosinophilic chronic obstructive pulmonary disease

…, GJ Criner, HAM Kerstjens, S Korn… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic
phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed …
Save Cite Cited by 476 Related articles All 9 versions

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

…, P Chanez, R Leigh, PM O'Byrne, S Korn… - The Lancet …, 2015 - thelancet.com
Background Interleukin 13 is a central mediator of asthma. Tralokinumab is a human
interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two …
Save Cite Cited by 403 Related articles All 8 versions
[HTML] nejm.org

[HTML][HTML] Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme

…, KM Beeh, D Kappeler, S Korn… - … England Journal of …, 2015 - Mass Medical Soc
Background The most prevalent phenotype of asthma is characterized by eosinophil-dominated
inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of …
Save Cite Cited by 327 Related articles All 6 versions
[HTML] univ-brest.fr

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

…, S Ballenberger, M Rolke, S Korn… - The lancet respiratory …, 2019 - thelancet.com
Background Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal
antibody that has been shown to safely reduce exacerbations and improve lung function for …
Save Cite Cited by 283 Related articles All 27 versions

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

…, CE Brightling, P Kuna, S Korn… - The Lancet …, 2022 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …
Save Cite Cited by 114 Related articles All 9 versions